CSTL
Castle Biosciences, Inc. [CSTL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CSTL Stock Summary
Top 10 Correlated Stocks
CSTL
In the News
CSTL Financial details
Company Rating
Neutral
Market Cap
550.65M
Income
-57.47M
Revenue
219.79M
Book val./share
14.48
Cash/share
8.99
Dividend
-
Dividend %
-
Employees
610
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-7.45
Forward P/E
-
PEG
4.53
P/S
2.94
P/B
1.46
P/C
2.13
P/FCF
-13.48
Quick Ratio
7.34
Current Ratio
7.7
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-2.16
EPS next Y
-
EPS next Q
-
EPS this Y
-17.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
33.48%
Revenue Q/Q
7.52%
EPS Q/Q
-63.31%
-
-
-
-
SMA20
-
SMA50
-16.67%
SMA100
-
Inst Own
66.36%
Inst Trans
0.77%
ROA
-17%
ROE
-19%
ROC
-0.21%
Gross Margin
78%
Oper. Margin
-45%
Profit Margin
-39%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.26-26.7
52W High
-26.23%
52W Low
+113.11%
RSI
42
Rel Volume
0.31
Avg Volume
246.31K
Volume
76.55K
Perf Week
-7.7%
Perf Month
-7.74%
Perf Quarter
46.86%
Perf Half Y
41.34%
-
-
-
-
Beta
0.924
-
-
Volatility
0.36%, 1.07%
Prev Close
-0.1%
Price
19.18
Change
1.8%
CSTL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.04 | 3.31 | 3.74 | 5.26 | 8.2 | |
| Net income per share | 0.61 | -0.54 | -1.24 | -2.58 | -2.14 | |
| Operating cash flow per share | 0.82 | 0.52 | -0.76 | -1.6 | -0.01 | |
| Free cash flow per share | 0.71 | 0.27 | -0.89 | -1.81 | -0.51 | |
| Cash per share | 11.52 | 21.65 | 13.11 | 9.93 | 9.07 | |
| Book value per share | 9.92 | 21.96 | 16.38 | 15.32 | 14.6 | |
| Tangible book value per share | 9.92 | 21.96 | 12.84 | 10.47 | 10.22 | |
| Share holders equity per share | 9.92 | 21.96 | 16.38 | 15.32 | 14.6 | |
| Interest debt per share | 3.46 | 0.14 | 0.32 | 0.51 | 0.57 | |
| Market cap | 295.03M | 1.27B | 1.08B | 613.31M | 578.39M | |
| Enterprise value | 221.31M | 861.23M | 756.07M | 503.67M | 494.86M | |
| P/E ratio | 55.91 | -123.6 | -34.44 | -9.14 | -10.06 | |
| Price to sales ratio | 5.69 | 20.29 | 11.45 | 4.48 | 2.63 | |
| POCF ratio | 42.06 | 128.85 | -56.77 | -14.72 | -4.28K | |
| PFCF ratio | 48.54 | 248.55 | -47.97 | -12.97 | -42.05 | |
| P/B Ratio | 3.47 | 3.06 | 2.62 | 1.54 | 1.48 | |
| PTB ratio | 3.47 | 3.06 | 2.62 | 1.54 | 1.48 | |
| EV to sales | 4.27 | 13.75 | 8.04 | 3.68 | 2.25 | |
| Enterprise value over EBITDA | 43.69 | -151.17 | -20.66 | -6.57 | -8.89 | |
| EV to operating cash flow | 31.55 | 87.3 | -39.83 | -12.09 | -3.67K | |
| EV to free cash flow | 36.41 | 168.41 | -33.65 | -10.65 | -35.97 | |
| Earnings yield | 0.02 | -0.01 | -0.03 | -0.11 | -0.1 | |
| Free cash flow yield | 0.02 | 0 | -0.02 | -0.08 | -0.02 | |
| Debt to equity | 0.3 | 0 | 0.02 | 0.03 | 0.04 | |
| Debt to assets | 0.21 | 0 | 0.02 | 0.03 | 0.03 | |
| Net debt to EBITDA | -14.56 | 71.94 | 8.78 | 1.43 | 1.5 | |
| Current ratio | 7.63 | 20.58 | 14.21 | 8.09 | 6.2 | |
| Interest coverage | 1.03 | -2.48 | -40.08K | -5.36K | -6.18K | |
| Income quality | 1.33 | -0.96 | 0.61 | 0.62 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.1 | -0.03 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0.41 | 0.3 | |
| Research and developement to revenue | 0.14 | 0.21 | 0.32 | 0.33 | 0.24 | |
| Intangibles to total assets | 0 | 0 | 0.19 | 0.28 | 0.25 | |
| Capex to operating cash flow | -0.13 | -0.48 | 0.18 | 0.14 | 100.9 | |
| Capex to revenue | -0.02 | -0.08 | -0.04 | -0.04 | -0.06 | |
| Capex to depreciation | -2.62 | -10.07 | -1.02 | -0.53 | -1.1 | |
| Stock based compensation to revenue | 0.02 | 0.13 | 0.23 | 0.27 | 0.23 | |
| Graham number | 11.71 | 16.38 | 21.42 | 29.8 | 26.54 | |
| ROIC | 0.04 | -0.02 | -0.07 | -0.21 | -0.16 | |
| Return on tangible assets | 0.04 | -0.02 | -0.08 | -0.21 | -0.16 | |
| Graham Net | 8.83 | 20.97 | 11.65 | 8.83 | 7.06 | |
| Working capital | 101.39M | 408.72M | 328.86M | 256.16M | 247.97M | |
| Tangible asset value | 85.11M | 415.69M | 322.82M | 272.8M | 273.93M | |
| Net current asset value | 82.05M | 405.96M | 302.91M | 244.11M | 209.09M | |
| Invested capital | 0.3 | 0 | 0.02 | 0.03 | 0.04 | |
| Average receivables | 13.37M | 13.7M | 15.02M | 20.38M | 30.89M | |
| Average payables | 1.66M | 1.98M | 2.32M | 3.64M | 7.5M | |
| Average inventory | 1.06M | 1.73M | 2.12M | 3M | 5.96M | |
| Days sales outstanding | 103.09 | 74.34 | 67.05 | 62.53 | 63.61 | |
| Days payables outstanding | 93.12 | 79.07 | 58.73 | 53.95 | 67.46 | |
| Days of inventory on hand | 61.77 | 83.55 | 46.62 | 45.38 | 52.18 | |
| Receivables turnover | 3.54 | 4.91 | 5.44 | 5.84 | 5.74 | |
| Payables turnover | 3.92 | 4.62 | 6.21 | 6.77 | 5.41 | |
| Inventory turnover | 5.91 | 4.37 | 7.83 | 8.04 | 6.99 | |
| ROE | 0.06 | -0.02 | -0.08 | -0.17 | -0.15 | |
| Capex per share | -0.11 | -0.25 | -0.14 | -0.22 | -0.51 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.45 | 1.58 | 1.88 | 2.29 | 2.45 | |
| Net income per share | -0.78 | -1.1 | -0.7 | -0.26 | -0.1 | |
| Operating cash flow per share | -0.23 | -0.96 | -0.14 | 0.19 | 0.89 | |
| Free cash flow per share | -0.29 | -1.08 | -0.29 | 0.1 | 0.75 | |
| Cash per share | 9.8 | 8.72 | 8.44 | 8.56 | 8.99 | |
| Book value per share | 15.12 | 14.48 | 14.17 | 14.38 | 14.48 | |
| Tangible book value per share | 10.33 | 9.81 | 9.61 | 9.92 | 10.13 | |
| Share holders equity per share | 15.12 | 14.48 | 14.17 | 14.38 | 14.48 | |
| Interest debt per share | 0.5 | 0.48 | 0.54 | 0.54 | 0.57 | |
| Market cap | 621.46M | 604.51M | 366.78M | 453.23M | 583.31M | |
| Enterprise value | 511.82M | 502.57M | 285.3M | 376.53M | 499.78M | |
| P/E ratio | -7.54 | -5.17 | -4.88 | -16.41 | -56.52 | |
| Price to sales ratio | 16.21 | 14.38 | 7.32 | 7.37 | 8.82 | |
| POCF ratio | -103.58 | -23.76 | -96.88 | 90.43 | 24.23 | |
| PFCF ratio | -79.81 | -21.01 | -46.9 | 177.25 | 28.76 | |
| P/B Ratio | 1.56 | 1.57 | 0.97 | 1.17 | 1.49 | |
| PTB ratio | 1.56 | 1.57 | 0.97 | 1.17 | 1.49 | |
| EV to sales | 13.35 | 11.96 | 5.69 | 6.12 | 7.56 | |
| Enterprise value over EBITDA | -27.46 | -19.11 | -18.15 | -101.85 | -205.33 | |
| EV to operating cash flow | -85.3 | -19.76 | -75.36 | 75.13 | 20.76 | |
| EV to free cash flow | -65.73 | -17.46 | -36.48 | 147.25 | 24.64 | |
| Earnings yield | -0.03 | -0.05 | -0.05 | -0.02 | 0 | |
| Free cash flow yield | -0.01 | -0.05 | -0.02 | 0.01 | 0.03 | |
| Debt to equity | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net debt to EBITDA | 5.88 | 3.88 | 5.18 | 20.75 | 34.32 | |
| Current ratio | 8.09 | 8.99 | 7.98 | 7.7 | 6.2 | |
| Interest coverage | -5.78K | -7.88K | -7.05K | -4.82K | -2.83K | |
| Income quality | 0.29 | 0.87 | 0.2 | -0.73 | -9.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.08 | -0.01 | -0.02 | -0.04 | 0 | |
| Sales general and administrative to revenue | 0.79 | 0.4 | 0.33 | 0.26 | 0.26 | |
| Research and developement to revenue | 0.29 | 0.34 | 0.27 | 0.21 | 0.2 | |
| Intangibles to total assets | 0.28 | 0.29 | 0.29 | 0.27 | 0.25 | |
| Capex to operating cash flow | 0.3 | 0.13 | 1.07 | -0.49 | -0.16 | |
| Capex to revenue | -0.05 | -0.08 | -0.08 | -0.04 | -0.06 | |
| Capex to depreciation | -0.63 | -1.15 | -1.33 | -0.77 | -1.18 | |
| Stock based compensation to revenue | 0.26 | 0.32 | 0.26 | 0.21 | 0.18 | |
| Graham number | 16.3 | 18.91 | 14.96 | 9.12 | 5.58 | |
| ROIC | -0.05 | -0.08 | -0.05 | -0.02 | -0.01 | |
| Return on tangible assets | -0.06 | -0.1 | -0.06 | -0.02 | -0.01 | |
| Graham Net | 8.71 | 8.02 | 7.68 | 7.83 | 7 | |
| Working capital | 256.16M | 240.96M | 235.34M | 243.3M | 247.97M | |
| Tangible asset value | 272.8M | 261.02M | 256.89M | 266.18M | 273.93M | |
| Net current asset value | 244.11M | 229.36M | 222.42M | 229.39M | 209.09M | |
| Invested capital | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Average receivables | 23.16M | 25.6M | 29.52M | 34.16M | 37.65M | |
| Average payables | 5.25M | 7.35M | 8.55M | 7.03M | 8.6M | |
| Average inventory | 3.89M | 4.25M | 5.32M | 5.95M | 6.86M | |
| Days sales outstanding | 55.11 | 59.36 | 56.21 | 54.16 | 52.14 | |
| Days payables outstanding | 44.73 | 88.05 | 58.07 | 55.09 | 61.22 | |
| Days of inventory on hand | 37.63 | 39.95 | 49.82 | 45.87 | 47.36 | |
| Receivables turnover | 1.63 | 1.52 | 1.6 | 1.66 | 1.73 | |
| Payables turnover | 2.01 | 1.02 | 1.55 | 1.63 | 1.47 | |
| Inventory turnover | 2.39 | 2.25 | 1.81 | 1.96 | 1.9 | |
| ROE | -0.05 | -0.08 | -0.05 | -0.02 | -0.01 | |
| Capex per share | -0.07 | -0.13 | -0.15 | -0.09 | -0.14 |
CSTL Frequently Asked Questions
What is Castle Biosciences, Inc. stock symbol ?
Castle Biosciences, Inc. is a US stock , located in Friendswood of Tx and trading under the symbol CSTL
What is Castle Biosciences, Inc. stock quote today ?
Castle Biosciences, Inc. stock price is $19.18 today.
Is Castle Biosciences, Inc. stock public?
Yes, Castle Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 246.31K
- Market Capitalization 550.65M
- Employee 610
- CEO Mr. Derek J. Maetzold
- Headquarters Friendswood,TX,US
- IPO Date 2019-07-25
-
Website
https://castlebiosciences.com 
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
